Nivolumab [nivolumab]
topical
461
- Terms
-
Opdivo
-
BMS-936558
MDX-1106
ONO-4538
Opdivo
Persistent link
https://www.medvik.cz/link/D000077594
Definition
A genetically engineered, fully humanized immunoglobulin G4 monoclonal antibody that binds to the PD-1 RECEPTOR, activating an immune response to tumor cells. It is used as monotherapy or in combination with IPILIMUMAB for the treatment of advanced malignant MELANOMA. It is also used in the treatment of advanced or recurring NON-SMALL CELL LUNG CANCER; RENAL CELL CARCINOMA; and HODGKIN'S LYMPHOMA.
- DUI
- D000077594 MeSH Browser
- CUI
- M0585694
- History note
- 2019 (2010)
- Public note
- 2019; NIVOLUMAB was indexed under ANTIBODIES, MONOCLONAL 2010-2018
Allowable subheadings
- AD
- administration & dosage 115
- AE
- adverse effects 68
- AN
- analysis
- BI
- biosynthesis
- BL
- blood
- CF
- cerebrospinal fluid
- CH
- chemistry
- CL
- classification
- DE
- drug effects 1
- EC
- economics 14
- GE
- genetics
- HI
- history
- IM
- immunology
- IP
- isolation & purification
- ME
- metabolism
- PK
- pharmacokinetics 2
- PD
- pharmacology 103
- PH
- physiology
- PO
- poisoning
- RE
- radiation effects
- TU
- therapeutic use 233
- TO
- toxicity 2
- UL
- ultrastructure
- UR
- urine
...
Occurrences in Medvik records
D
Chemicals and Drugs